Versi
Titl
Titl
ProDatProEU
ActMePro
ProMaHolJoin
ResObj
CouAut
No
ion 01, dated 1
e Page
le
otocol Versionte of Last Verotocol PAS Registe
tive Substancdicinal Produ
oduct Referen
ocedure Numbarketing Authlder(s) nt PASS
search Questijectives
untry(-ies) ofthor
use or disclos
Lopinavir/ritoP15-452 Prot
17 August 201
n Identifier rsion of
er Number
ceuctnce
ber horisation
ion and
f Study
This study
sure outside A
onavir and Lamtocol
15
ProSpectivEffectiveneTreatment-Settings of
P15-452
17 Aug 20
Not applica
Not applica
Not applica
Not applica
Not applica
AbbVie DeLudwigsha
Not applica
To assess t(lopinavir/treatment-eplasma HIVtimepoint oFederation
Russian Fe
y will be condConf
AbbVie is per
mivudine
ve, MultI-Centess of Dual Th-Experienced f the Russian F
15
able
able
able
able
able
eutschland Gmafen, Germany
able
the virologic eritonavir (LPV
experienced HV-1 RNA leveof treatment in
n.
ederation
ucted in compfidential Inforrmitted witho
ter, ObservatioheraPy (LopinHIV Infected Federation (SI
mbH & Co. KGy
effectiveness oV/r) + lamivu
HIV-1 infectedel (for at least n the routine c
pliance with trmation out prior writ
onal PrograMnavir/ritonavirPatients in the
IMPLE)
G, Knollstrass
of dual therapyudine (3TC)) ind patients with
6 months) at tclinical setting
this protocol.
tten authoriza
M to Assess ther + Lamivudine Routine Clin
se 67061
y n population o
h an undetectabthe 48 week s of the Russia
.
ation from Ab
1
e nE) in nical
of ble
an
bbVie.
Versi
Mar
Ma
MA
ion 01, dated 1
rketing A
arketing Auth
AH Contact P
Lopinavir/ritoP15-452 Prot
17 August 201
Authorisa
horisation Hol
Person
onavir and Lamtocol
15
ation Ho
lder(s) AL
N
mivudine
lder(s)
AbbVie DeutscLudwigshafen,
Not applicable
chland GmbH Germany
& Co. KG, KKnollstrasse 67
2
7061
Versi
1.0
1.02.03.04.05.06.07.07.17.28.08.18.29.09.19.29.39.49.59.69.79.89.99.109.109.109.119.129.139.149.159.16
ion 01, dated 1
00.10.2
4
Lopinavir/ritoP15-452 Prot
17 August 201
Table
Table of AbbreviaResponsiAbstractAmendmMilestonRationalBackgrounRationale .ResearchPrimary ObSecondaryResearchStudy DesiProduct SuSetting .....Program DInvestigatoInclusion CExclusion DescriptionTerminatioEndpoints Primary EnSecondaryData SourcStudy SizeData ManaData AnalyQuality CoLimitation
onavir and Lamtocol
15
of Conte
Contentsations .....ible Partit ..............
ments andnes ...........le and Bacnd .................................
h Questionbjective ..... Objectives h Methodign .............upply ............................
Duration ......or selection Criteria ......Criteria .....n of Activiton of the Pro..................ndpoint ...... Endpointsces .............e .................agement .....ysis ............ontrol .........ns of the Res
mivudine
ents
s ...............................ies ............................ Updates.................ckground....................................n and Ob....................................s ......................................................................................criteria ..........................................
ties .............ogram ........................................................................................................................................................search Meth
................
................
................
................
................
................d .....................................................
bjectives ...........................................................................................................................................................................................................................................................................................................................................................................................
hods ............
................
................
................
................
................
................
..................................................................................................................................................................................................................................................................................................................................................................................................................................................................................
................
................
................
................
................
................
................
...................
...................
................
...................
...................
................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
3
...... 3
...... 5
...... 6
...... 7
.... 10
.... 10
.... 10
...... 10
...... 12
.... 12
...... 12
...... 12
.... 13
...... 13
...... 13
...... 13
...... 13
...... 14
...... 14
...... 15
...... 15
...... 18
...... 19
...... 19
...... 19
...... 20
...... 20
...... 20
...... 21
...... 24
...... 25
Versi
9.1710.011.011.111.111.111.111.111.111.111.211.211.212.0
13.0
ion 01, dated 1
00
.1
.2
.3
.4
.5
.6
.1
.20
0
Lopinavir/ritoP15-452 Prot
17 August 201
Other AspeProtectioManagemMedical CAdverse EvSeverity ...RelationshSerious AdSerious AdPregnancyProduct CoDefinition Reporting .Plans forResults ..Referenc
onavir and Lamtocol
15
ects ............on of Humment and omplaints ..vent Definit..................
hip to Pharmdverse Evendverse Even Reporting .omplaint ........................................r Dissemin................ces ...........
mivudine
..................man Subje
Reportin..................tion and Ser..................
maceutical Prnt Collectionnt Reporting........................................................................nating an................................
...................ects .........ng of Com...................rious Adver...................roduct ........n Period ......g ..............................................................................................
nd Commu................................
...................................
mplaints .......................rse Event Ca........................................................................................................................................................unicating ................................
...................
................
................
...................ategories ............................................................................................................................................................Study
................
................
4
...... 25
.... 25
.... 26
...... 26
...... 26
...... 27
...... 28
...... 28
...... 28
...... 29
...... 29
...... 29
...... 30
.... 31
.... 31
Versi
2.0
3TC
AID
AE
ART
CI
CRA
CRO
CVD
eCR
EDC
GPV
HAA
HIV
IEC
LPV
MA
Med
NC=
NRT
PI
PMO
RNA
SAE
ion 01, dated 1
C
DS
T
A
O
D
RF
C
V
ART
V
C
V/r
AH
dDRA
=F
TI
OS
A
E
Lopinavir/ritoP15-452 Prot
17 August 201
Abbre
onavir and Lamtocol
15
eviations
Lamivacqui
Adve
Antire
Confi
Clinic
Contr
Cardi
Electr
Electr
Globa
Highl
Huma
Indep
Lopin
Mark
Medic
Non-c
Nucle
Protea
Post-M
Ribon
Seriou
mivudine
vudine red immune d
rse event
etroviral Ther
idential Interv
cal Research A
ract Research
iovascular Dis
ronic Case rep
ronic Data Cap
al Pharmacovi
ly Active Anti
an Immunodef
pendent Ethics
navir/ ritonavir
keting Applicat
cal Dictionary
completer=Fa
eoside Reverse
ase Inhibitor
Marketing Ob
nucleic acid
us adverse eve
deficiency synd
rapy
val
Associate
Organization
sease
port form
pture
igilance
i-Retroviral Th
ficiency Virus
s Committee
r
tion Holder
y for Regulato
ailure algorithm
e Transcriptas
bservational St
ent
drome
herapy
s
ry Activities
m
se Inhibitor
tudy
5
Versi
3.0Abb
Cont
ion 01, dated 1
Vie
tract Resear
Lopinavir/ritoP15-452 Prot
17 August 201
Respo
rch Organiz
onavir and Lamtocol
15
onsible P
zation (CRO
mivudine
Parties
O)
6
Versi
4.0
Title
(Lopi
Clinic
Ratio
assoc
nucle
exam
didan
abaca
that h
antivi
patien
LPV/
GAR
effica
maint
Effica
overw
treatm
ion 01, dated 1
: Prospective
inavir/ritonavi
cal Settings of
onale and B
ciated with th
eos(t)ide analo
mple, some NR
nosine) and ki
avir in some c
has been wide
iral potency o
nts in a numbe
/r+3TC dual
RDEL and OLE
acy and comp
tenance therap
acy data for L
whelmingly fro
ment-experien
Lopinavir/ritoP15-452 Prot
17 August 201
Abstra
, Multi-Center
ir + Lamivudin
f the Russian F
Background: he use of a
ogues (NRTIs
RTIs can caus
idney dysfunc
ohort studies
ely used as a f
of LPV/r (lop
er of different
therapy has b
E studies resp
parable safety
py in virologic
LPV/r+3TC d
om OLE study
nced HIV-1 inf
onavir and Lamtocol
15
act
r, Observation
ne) in Treatme
Federation
Standard o
a triple antire
s) (4). NRTIs
se anemia (zid
ction (tenofovi
(5 - 7). Lamiv
first line drug
pinavir/ritonav
clinical trials,
been studied
pectively (1-3)
to LPV/r + 2
cally suppresse
dual therapy da
y (1) whereas
fected patients
mivudine
nal Program to
ent-Experienc
of care treatm
etroviral ther
s are not alwa
dovudine), neu
ir). Cardiovas
vudine (3TC)
for the treatm
vir) has been
, for periods o
in HIV-1-naï
). Over 48 we
2 NRTIs, as f
ed patients in
ata from treatm
no data exists
s in routine cli
o Assess the E
ced HIV-1 Infe
ment of HIV-
rapy (ART)
ays well tolera
urotoxicity an
scular disease
is an effective
ment of HIV in
clearly demon
of up to seven y
ïve and HIV-
eeks, LPV/r +
first line regim
OLE study (1
ment-experien
s on that effect
inical settings
ffectiveness o
ected Patients
-1-infected pa
with regimen
ated (short an
nd lipodystroph
e (CVD) is als
e NRTI with g
nfected adults
nstrated in a
years (13-14).
-1 experience
3TC demonst
men in GARD
-3).
nced HIV-1 po
tiveness of LP
of the Russian
of Dual Therap
in the Routine
atients is usu
ns including
nd long term).
hy (stavudine
so associated
good safety pr
and children.
wide spectrum
.
ed patients in
trated non-infe
DEL study an
opulations are
PV/r + 3TC in
n Federation.
7
py
e
ually
two
. For
and
with
rofile
The
m of
n the
ferior
nd as
Versi
Resea
Prima
To as
popul
level
Russi
Secon
1
2
3
4
5
Study
contr
Popu
plasm
as me
Endp
Prima
1
Secon
1
2
3
4
5
ion 01, dated 1
arch Question
ary Objective
ssess the virolo
lation of treat
(for at least 6
ian Federation
ndary Objectiv
1. To evalua
2. To evalua
3. To assess
4. To evalua
5. To evalua
y Design: Thi
ol group.
ulation: HIV-
ma HIV-1 RNA
edically appro
points
ary endpoint
1. Proportion
level at we
ndary endpoin
1. Proportion
week 24 o
2. Absolute v
the baselin
3. Absolute v
baseline.
4. Proportion
5. Absolute v
waist circu
Lopinavir/ritoP15-452 Prot
17 August 201
n and Object
ogic effectiven
tment-experien
6 months) at th
n. ves
ate virologic ef
ate immune rec
the developm
ate metabolic
ate the safety a
is is a non-inte
-1 infected pat
A level for at l
priate to LPV
n of patients o
eek 48 of the o
nts
n of patients o
of the observat
values of HIV
ne (untransfor
values of CD4
n of patients w
values at week
umference in
onavir and Lamtocol
15
tives:
ness of dual th
nced HIV-1 in
he 48 week ti
ffectiveness of
constitution on
ment level of dr
and anthropom
and tolerability
erventional, pr
tients aged 18
least 6 months
V/r + 3TC in th
on dual therap
observational
on dual therap
tional period.
V-1- RNA vira
rmed and base
4+ T-cell coun
who develop re
ks 24 and 48 a
cm) as compa
mivudine
herapy (lopina
nfected patien
imepoint of tr
f dual therapy
n the dual ther
rug resistance
metric parame
y of dual thera
roduct-focused
years and old
s (two consequ
he routine clini
py (LPV/r + 3
period.
py (LPV/r + 3
al loader at we
e-10 logarithm
nts at weeks 2
esistance to ea
and changes of
ared to the base
avir/ ritonavir
nts with an un
eatment in the
y at week 24.
rapy at weeks
over 48 week
eters change ov
apy (LPV/r + 3
d, longitudinal
der on any tripl
uently plasma
ical settings.
3TC) with un
3TC) with und
eeks 24 and 48
m transformed d
24 and 48 and
ach drug in the
f anthropomet
eline.
(LPV/r) + lam
ndetectable pla
e routine clini
24 and 48.
ks of treatment
ver 48 weeks o
3TC)
l and multi-ce
le HAART w
HIV-1 RNA
ndetectable pla
detectable HIV
8 and the chan
data).
d the change a
e study regime
tric measurem
mivudine (3TC
asma HIV-1 R
ical settings o
t.
of treatment.
enter study wit
with undetectab
levels) transfe
asma HIV-1 R
V-1- RNA lev
nge as compare
as compared to
en.
ments (arm, hip
8
C)) in
RNA
f the
th no
ble
erred
RNA
vel at
ed to
o the
p and
Versi
6
7
Data
sourc
may i
dispe
Study
infect
arm
obser
have
of dro
norm
propo
numb
Data
gener
patien
Quali
additi
gener
Miles
Start
End o
Interi
Final
ion 01, dated 1
6. Absolute
total chol
baseline.
7. Proportion
causing tr
period.
Sources: Dat
ce documents a
include hospit
ensing and oth
y Size: The O
ted patients re
at 48 weeks,
rvational prog
undetectable
opout is 196, a
mal distribution
ortion for an
ber of enrolled
Analysis: Si
ration of descr
nts, mean, stan
itative variable
ion, two-sided
rated for visua
stones:
of Data Colle
of Data Collec
im Report:
Report of Stu
Lopinavir/ritoP15-452 Prot
17 August 201
values at wee
lesterol, LDL-
n of patients
reatment disco
ta for the study
at the center. S
tal records, cli
er records, rec
OLE study (1
emained suppr
with non-inf
ram, it is estim
plasma HIV-1
a Simple Asym
n will extend
expected prop
d patients will
ince this is an
riptive summa
ndard deviatio
es will be sum
d 95% confide
al interpretatio
ction: 1
ction: 1
1
udy Results: 1
onavir and Lamtocol
15
eks 24 and 48
- and HDL-ch
with AEs (
ontinuations],
y will be colle
Source docum
inical and offic
corded data fro
1) reported th
ressed (undete
feriority to th
mated that a s
1 RNA level a
mptotic two-s
5% (i.e. half
portion of 85%
constitute 216
open-label, no
ary statistics. Q
on, median, 1s
mmarized with
ence intervals w
on of the result
6 October 201
4 April 2017
15 November 2
10 December 2
mivudine
8 and change
holesterol, tri
non-serious A
SAEs, [includ
ected from clin
ments will be o
ce charts, labo
om automated
at 87.8% of p
ectable plasma
he LPV/r plu
similar percent
at week 48. W
sided 95% con
width of the
%. Considerin
6.
on-randomized
Quantitative va
t quartile, 3rd
h the number a
will be genera
ts, as appropri
15
2016
2017
es of metaboli
igclycerides, c
AEs spontane
ding SAEs tha
nical interview
riginal docum
oratory data/in
d instruments,
pre-suppressed
a HIV-1 RNA
us 2 NRTi co
tage of the pa
When the samp
nfidence interv
95% confiden
ng an approxi
d trial, the ana
ariables will b
quartile, mini
and proportion
ated for param
iate.
ic parameters
creatinine) as
eously reporte
at cause deaths
w with the pare
ments, data and
nformation, ph
etc.
d treatment-ex
A level) on the
ontrol arm. T
atients among
ple size witho
val for a single
nce interval) f
imate dropout
alyses will prim
be summarized
imum and max
n of patients in
meter estimates
(glucose, ins
compared to
ed [including
s] ) over the s
ent and from
d records. This
harmacy
xperienced HI
e LPV/r plus
Therefore, for
study sample
out a considera
e proportion u
from the obse
t rate about 1
marily involve
d with number
ximum values
n each category
s. Graphs may
9
ulin,
o the
AE
study
s
IV-1
3TC
this
will
ation
using
erved
10%,
e the
r of
s.
y. In
be
Versi
5.0
Not
6.0
Majo
StarEndStudInteRegFina
7.0
7.1
Stan
a trip
(NR
some
and
asso
In a
inter
and
may
and
ion 01, dated 1
applicable b
or study mil
rt of Data Colld of Data Colledy Progress Rerim Report: gistration in thal Report of S
ndard of care
ple antiretro
RTIs) (4). N
e NRTIs ca
didanosine
ciated with
addition, the
ractions wit
hepatitis C
be ineffect
in some cas
Lopinavir/ritoP15-452 Prot
17 August 201
Amend
by now.
Milest
lestones and
lection: ection:
Report:
he EU PAS regStudy Results:
Ration
Backgr
e treatment
oviral therap
NRTIs are n
an cause ane
e) and kidn
abacavir in
e selection
th drugs for
. Excluding
tive. And fin
ses may not
onavir and Lamtocol
15
dments a
ones
d their plann
gister
nale and
round
of HIV-1 in
py (ART) w
not always w
emia (zidov
ney dysfun
some cohor
of drugs in
r the treatm
g these inter
nally, the d
be available
mivudine
and Upda
ned dates ar
16 October 14 April 20N/A 15 NovembN/A 10 Decembe
Backgro
nfected pati
with regimen
well tolerat
vudine), neu
nction (teno
rt studies (5
n the regim
ment of com
ractions as
drugs includ
e for use for
ates
e as follows
2015 17
ber 2016
er 2017
ound
ents is usua
ns including
ed (short an
urotoxicity a
ofovir), car
5 - 7).
mens of AR
morbidities d
treatment f
ded in the st
r different re
s:
ally associat
g two nucleo
nd long ter
and lipodys
rdiovascular
RT should t
diseases suc
for HIV and
tandard tripl
easons.
ted with the
os(t)ide ana
rm). For ex
strophy (stav
r diseases i
take into a
ch as tuberc
d related di
le ART reg
10
use of
alogues
ample,
vudine
is also
ccount
culosis
iseases
gimens,
Versi
NRT
(PI)
studi
supp
load
Main
limit
first
susc
rend
antiv
spec
year
LPV
the
dem
line
patie
The
for t
3TC
gene
ion 01, dated 1
TI-sparing s
boosted wi
ies reportin
pression, the
d is usually
ntaining or
tation. 3TC
line drug
eptible to a
ders lamivud
viral potenc
ctrum of pat
rs (13-14).
V/r+3TC dua
GARDEL
monstrated n
regimen in
ents in OLE
cost of anti
the health sy
C may signif
eric ARV.
Lopinavir/ritoP15-452 Prot
17 August 201
studies have
ith ritonavir
ng non-infer
e proportion
y higher in
adding lam
is an effect
for the tre
a single poi
dine inactiv
cy of LPV/r
tients in a n
al therapy w
and OLE
on-inferior
GARDEL
E study (1-3)
iretroviral th
ystems (12)
ficantly red
onavir and Lamtocol
15
e historically
r (lopinavir
riority of th
n of patients
n the grou
mivudine (o
ive drug wi
atment of
int mutation
ve but also
r (lopinavir/
number of
was studied
studies res
efficacy an
study and a
).
herapy and
). As an add
duce the cos
mivudine
y focused o
r or darunav
his strategy
s showing o
ups treated
or 3TC) to
th good safe
HIV-1 infe
n in the HI
o impacts t
/ritonavir) h
different cl
d in HIV-1-
spectively (
nd comparab
as maintena
its cost imp
ded value, s
st of treatm
n monother
vir) (8, 9).
when used
one or more
d with boo
this strateg
ety profile t
ected adults
IV-1 genom
he viral re
has been cle
linical trials
naïve and H
(1-3). Over
ble safety t
ance therapy
plications ar
simplifying
ment, especia
rapy with a
However, a
following
e episodes o
osted PI m
gy could he
that has been
s and childr
me (M184V
plicative ca
early demon
s, for period
HIV-1 expe
r 48 week
to LPV/r +
y in virolog
re also incre
triple thera
ally as 3TC
protease in
although the
HAART-led
of detectabl
monotherapy
elp overcom
n widely use
ren. This d
V mutation)
apacity (11
nstrated in a
ds of up to
erience patie
s, LPV/r +
2 NRTIs, a
gically supp
easingly imp
apy to LPV
C is an estab
11
nhibitor
ere are
d viral
le viral
y (10).
me this
ed as a
drug is
which
). The
a wide
seven
ents in
+ 3TC
as first
pressed
portant
V/r plus
blished
Versi
7.2
Effic
popu
worl
the r
Expe
settin
the a
8.0
8.1
To a
lami
an un
of tr
8.2
1
2
3
4
5
ion 01, dated 1
cacy data
ulations are
ld effectiven
routine clini
erience of u
ngs could le
additional an
assess the
ivudine (3T
ndetectable
eatment in t
1. To evalu
2. To evalu
3. To asses
4. To eval
of treatm
5. To eval
Lopinavir/ritoP15-452 Prot
17 August 201
Rationa
for LPV/r+
overwhelm
ness of LPV
ical settings
using the dua
ead to its ad
nd less expe
Resea
Primary
virologic e
TC)) in popu
plasma HIV
the routine c
Second
uate the viro
uate the imm
ss the develo
uate the me
ment.
uate the saf
onavir and Lamtocol
15
ale
+3TC dual
mingly from
V/r + 3TC i
of the Russ
al therapy (L
ddition to th
ensive regim
arch Que
y Objectiv
effectivenes
ulation of tr
V-1 RNA le
clinical setti
dary Objec
ologic effect
mune recons
opment leve
etabolic and
fety and tole
mivudine
therapy da
m OLE study
in treatment
sian Federat
LPV/r+3TC
he National
men of choic
stion and
ve
s of dual
reatment-ex
evel (for at l
ings of the R
ctives
tiveness of d
stitution on
el of drug re
anthropome
erability of d
ata from tr
y (1) where
t-experience
tion.
C) regimen i
guidelines
ce for stakeh
d Object
therapy (lo
xperienced H
least 6 mon
Russian Fed
dual therapy
the dual the
esistance ov
etric parame
dual therapy
reatment-ex
as no data e
ed HIV-1 in
in the Russi
and provide
holders.
tives
opinavir/ rito
HIV-1 infec
nths) at the 4
deration.
y at week 24
erapy at wee
ver 48 weeks
eters change
y (LPV/r + 3
xperienced
exists on th
nfected patie
an routine c
e the advant
onavir (LPV
cted patient
48 week tim
4.
eks 24 and 4
s of treatme
e over 48 w
3TC)
12
HIV-1
hat real
ents in
clinical
tage of
V/r) +
ts with
mepoint
48.
nt.
weeks
Versi
9.0
9.1
This
cont
This
3TC
plasm
the r
9.2
As t
supp
presc
9.3
For p
15 n
9.4
Enro
LPV
label
telep
will
ion 01, dated 1
s is a non-in
trol group.
s study desi
C) in populat
ma HIV-1 R
routine clini
this is a pos
ply since the
cribed by th
purpose of
national and
ollment wil
V/r + 3TC w
l to all enr
phone conta
be organize
Lopinavir/ritoP15-452 Prot
17 August 201
Resea
Study D
nterventiona
gn will be
tion of treat
RNA level (
ical settings
Produc
st-marketing
e drug is be
he physician
Setting
this program
regional AI
Program
l start from
will be adm
rolled subje
act at 30 da
ed according
onavir and Lamtocol
15
arch Meth
Design
al, product-f
used to acc
ment-exper
(for at least
of the Russ
ct Supply
g observatio
eing used a
n under usua
g
m participan
IDS centers
m Duratio
m 16 Octob
ministrated a
ects. All en
ays after the
g to routine
mivudine
hods
focused, lon
cess the effe
rienced HIV
6 months) a
sian Federat
onal study, A
ccording to
al and custom
nts will be r
.
n
ber 2015 an
according to
nrolled patie
eir last dose
clinical pra
ngitudinal an
ectiveness o
V-1 infected
at the 48 we
tion.
AbbVie is N
o the approv
mary practi
recruited an
nd continue
o physician
ents will be
e in the stud
actice (appro
nd multi-cen
of the dual
patients wit
eek time poi
NOT involv
ved market
ce of physic
nd observed
e approxim
n’s prescript
e followed
dy. All visi
oximately ev
nter study w
therapy (LP
th an undete
int of treatm
ved in the p
label and is
cian prescrip
d in approxim
mately 6-8 m
tion and the
by a perso
its of the pr
very 3 mont
13
with no
PV/r +
ectable
ment in
product
s to be
ption.
mately
months
e local
onal or
rogram
ths).
Versi
9.5
In or
durin
9.6
ART
Patie
+ 3T
inter
wish
the f
1. A
2. Hcopias mclini(LPV
3. Cu
4. A
ion 01, dated 1
rder to assur
ng the recru
Physicia
Physicia
Availabi
Ability t
T therapy w
ent can be in
TC) due to
ractions, sid
h to simplify
following cr
ge 18 years
HIV-1 infectes/mL for a
medically apical settingsV/r + 3TC) n
umulative H
uthorization
Lopinavir/ritoP15-452 Prot
17 August 201
Investig
re credibilit
uitment proc
an licensed i
an is workin
ility of patie
to appropria
Inclusio
will be presc
ncluded in t
any reason
de effects, p
y regimen, a
riteria:
and older (
ted patientsat least 6 moppropriate ts. OR HIVno more tha
HAART exp
n (Consent)
onavir and Lamtocol
15
gator sele
ty of the fina
cess of phys
in infection
ng at a nation
ent populati
ately conduc
on Criteria
cribed by p
the study, if
n such as do
prevention o
actual regim
(male and fe
s on any tronths (two cto LPV/r +-1 infected an 60 days a
perience at l
for Use/Dis
mivudine
ction crite
al results th
sician/invest
diseases;
nal or region
on fulfilling
ct the observ
a
physician ac
f he/she will
ocumented
of long-term
men no long
emale).
riple HAARconsequently+ 3TC as d
patients wago.
least 6 mont
sclosure of D
eria
he below list
tigators:
nal AIDS ce
g the inclusi
vational pro
ccording to
l be switche
toxicity, m
m toxicity (
er recomme
RT with play plasma HI
decided by who were sw
ths.
Data signed
ted criteria w
enter;
ion/exclusio
ogram.
the routine
ed on the du
management
(pre-emptiv
ended, etc, a
asma HIV-1IV-1 RNA lthe physiciwitched on
d by the pati
will be cons
on criteria;
e clinical pr
ual therapy (
of potentia
ve switch), p
and will be
1 RNA levelevels) transian in the r
the dual th
ient.
14
sidered
ractice.
(LPV/r
al drug
patient
satisfy
el <50 sferred routine herapy
Versi
9.7
A pa
1
2
9.8
The consmonfollointer
ion 01, dated 1
atient will n
1. Has con(please s
2. Previous
patient visisulting physnths) when dow-up visit/rvals of pati
Lopinavir/ritoP15-452 Prot
17 August 201
Exclusi
ot be eligibl
ntraindicatiosee the lates
s participati
Descrip
its will be ssician. Howdual therapy/terminationent visits w
onavir and Lamtocol
15
ion Criteri
le for this P
ons for the st versions o
on in this pr
ption of Ac
cheduled bawever, it wy (LPV/r + n contact.
will not const
mivudine
ia
MOS if he/
treatment wof the locally
rogram.
ctivities
ased on rouwould be 5
3TC) will Failure to titute a brea
she fulfils th
with lopinay approved
utine clinica observatiobe adminisobserve th
ach or violat
he following
avir/ritonavilabels).
al practice anonal visits strated to thhese 3-montion of the p
g criterion:
ir and lamiv
nd prescript(approx. ev
he patient annth usual pprotocol.
15
vudine
tion of very 3 nd one ractice
Versi
Obs
ion 01, dated 1
Assignm
digit pat
Inclusion
Last ava
Last ava
Collectio
Last ava
Registra
Collectio
circumfe
Collectio
choleste
(mmol/L
SAEs m
ervational
Last ava
Last ava
was don
Last ava
level is d
was und
after 1 m
HIV-1 d
designat
Registra
Lopinavir/ritoP15-452 Prot
17 August 201
ment of pati
tient individ
n/exclusion
ailable CD4+
ailable HIV-
on of releva
ailable resist
ation of start
on of anth
erence in cm
on of labor
rol (mmol
L), creatinin
monitoring
visits 2 and
ailable CD4+
ailable HIV-
ne or planned
ailable resis
detectable a
detectable, d
month. If the
drug resistan
ted these tes
ation of pres
onavir and Lamtocol
15
ient’s identi
dual enrollm
n criteria ver
+ T-cell cou
-1- RNA tes
ant medical
tance test re
t date and do
hropometric
m).
ratory tests
/L), LDL-
ne(μmol/L),
d 4
+ T-cell cou
-1- RNA tes
d both test a
stance test r
at a given vi
data of conf
e confirmat
nce genotyp
sts and the s
scribed med
mivudine
ification num
ment number
rification
unt test resu
st result
history
esult for LPV
oses of pres
c parameter
results (glu
and HDL
ALT (u/l),
unt test resu
st result. If
and re-test r
result for L
isit and at th
firmatory pl
ory plasma
ing test will
such informa
ications
mber (two-
r)
ult
V/r and 3TC
scribed LPV
rs measure
ucose (mmo
L-cholestero
AST (u/l)).
ult
last test res
results will b
LPV/r and 3
he previous
lasma HIV-
HIV-1 RNA
l be collecte
ation is avai
digit center
C, if any
V/r and 3TC
ement (arm
ol/L), insuli
ol (mmol/L
ult was dete
be collected
3TC (if pla
visit the pla
1 RNA test
A is >400 c
ed, if the con
ilable)
r number +
m, hip and
in (μEq/ml)
L), trigclyc
ectable and
d
asma HIV-1
asma HIV-1
t will be co
copies/mL, d
nsulting phy
17
three-
waist
), total
cerides
re-test
1 RNA
1 RNA
llected
data of
ysician
Versi
Obs
Follo
cont
9.9
Deci
parti
treat
ion 01, dated 1
Monitor
causing
ervational
Last ava
Last ava
was don
Last ava
Registra
Collectio
circumfe
Collectio
choleste
(mmol/L
Monitor
causing
ow-up Visi
tact
Monitor
causing
Complet
patient p
will be c
ision regard
icipant will
tment discon
Lopinavir/ritoP15-452 Prot
17 August 201
ring of AE
treatment d
visits 3 and
ailable CD4+
ailable HIV-
ne or planned
ailable resist
ation of pres
on of anth
erence in cm
on of labor
rol (mmol
L), creatinin
ring of AE
treatment d
it/Terminat
ring of AE
treatment d
tion form of
prematurely
collected
Termin
ding the di
be ultimate
ntinuation w
onavir and Lamtocol
15
Es (non-seri
discontinuati
d 5
+ T-cell cou
-1- RNA tes
d both test a
tance test re
scribed med
hropometric
m)
ratory tests
/L), LDL-
ne(μmol/L),
Es (non-seri
discontinuati
tion or Ear
Es (non-seri
discontinua
f eCRF has
y discontinu
ation of th
iscontinuatio
ely based on
will be colle
mivudine
ious AEs s
ions], SAEs
unt test resu
st result. If
and re-test r
esult for LPV
ications
c parameter
results (glu
and HDL
ALT (u/l),
ious AEs s
ions], SAEs
rly Termin
ious AEs s
ations], SAE
to be comp
ued the study
he Program
on of the
n the treatin
cted and sum
spontaneous
s, [including
ult
last test res
results will b
V/r and 3TC
rs measure
ucose (mm
L-cholestero
AST (u/l))
spontaneous
s, [including
ation Cont
spontaneous
Es, [includi
leted at the
y. Reason f
m
dual therap
ng physician
mmarized in
sly reported
g SAEs that
ult was dete
be collected
C
ement (arm
ol/L), insul
ol (mmol/L
sly reported
g SAEs that
tact - Perso
sly reported
ng SAEs th
end of the s
for prematur
py (LPV/r
n’s judgmen
n the study
d) [includin
cause death
ectable and
d
m, hip and
lin (μEq/ml
L), trigclyc
d) [includin
cause death
onal or tele
d) [includin
hat cause d
study and al
re discontin
+ 3TC) for
nt. The reas
report.
18
ng AE
hs]
re-test
waist
l), otal
cerides
ng AE
hs]
ephone
ng AE
deaths]
lso if a
nuation
r each
son for
Versi
Abb
done
9.10
9.10
1
9.10
1
2
3
4
5
6
7
ion 01, dated 1
Vie may sto
e to particip
0
0.1
1. Proporti
RNA lev
0.2
1. Proporti
RNA lev
2. Absolute
change
transform
3. Absolute
compare
4. Proporti
regimen
5. Absolute
measure
baseline
6. Absolute
(glucose
creatinin
7. Proport
[includin
Lopinavir/ritoP15-452 Prot
17 August 201
op the prog
ants if they
Endpoi
Primary
on of patien
vel at week
Second
on of patie
vel at week
e values of
as compar
med data).
e values of
ed to the bas
on of patien
n.
e values a
ements (arm
.
e values at
e, insulin,
ne, ALT, AS
ion of pat
ng AE cau
onavir and Lamtocol
15
gram in case
continue to
ints
y Endpoin
nts on dual
48 of the ob
dary Endp
ents on dual
24 of the ob
f HIV-1- R
red to the
CD4+ T-ce
seline.
nts who dev
at the wee
m, hip and
the weeks
total chole
ST) as comp
tients with
using treatm
mivudine
e there is ev
o participate
nt
l therapy (L
bservational
oints
l therapy (L
bservational
RNA viral lo
baseline (
ell counts at
velop resist
eks 24 and
waist circu
24 and 48
sterol, LDL
pared to the
AEs (non
ment discont
vidence of h
.
LPV/r + 3TC
l period.
LPV/r + 3T
l period.
oader at th
(untransform
t the weeks
ance to eac
d 48 and
umference
8 and chang
L- and HD
baseline.
n-serious A
tinuations],
harm that is
C) with und
TC) with un
he weeks 24
med and b
24 and 48
ch class of d
changes o
in cm) as
ges of meta
DL-choleste
AEs spontan
SAEs, [inc
done or co
detectable H
ndetectable
4 and 48 a
base-10 log
and the cha
drugs in the
of anthropo
compared
abolic para
rol, triglyc
neously rep
cluding SAE
19
ould be
HIV-1-
HIV1-
nd the
garithm
ange as
e study
ometric
to the
meters
cerides,
ported)
Es that
Versi
9.11
Data
docu
This
phar
9.12
The
infec
LPV
arm.
the p
Whe
two-
exten
for a
num
9.13
For
eCR
and
subje
prog
ion 01, dated 1
cause d
(SOCs)
1
a for the stu
ument at the
s may includ
rmacy dispe
2
OLE study
cted patient
V/r plus 3TC
. Therefore,
patients amo
en the samp
-sided 95%
nd 5% (i.e.
an expected
mber of enrol
3
this progra
RF data man
reviewed/ap
ect enrolled
gram data fo
Lopinavir/ritoP15-452 Prot
17 August 201
eaths], with
and by frequ
Data So
udy will be
e center. So
de hospital
ensing and o
Study S
y (1) reporte
ts remained
C arm at 48
for this obs
ong study sa
ple size wit
confidence
half width
d proportion
lled patients
Data Ma
m electroni
nagement pla
pproved by
d in this pr
or AbbVie (
onavir and Lamtocol
15
h AEs orga
uency
ources
collected w
ource docum
records, clin
other records
Size
ed that 87.8
suppressed
weeks, wit
servational
ample will h
thout a cons
interval fo
of the 95%
of 85%. Co
s will consti
anagemen
ic Case rep
an and data
y AbbVie re
rogram. The
(or a CRO f
mivudine
anized acco
within clinic
ments will b
nical and of
s, recorded
8% of pre-s
d (undetect
th non-infer
program, it
have undete
sideration o
r a single p
% confidence
onsidering a
itute 216.
nt
port forms (
a validation
epresentativ
ese forms w
for data man
ording to S
cal interview
be original d
ffice charts,
data from au
suppressed t
table plasma
riority to the
is estimate
ctable plasm
of dropout i
proportion u
e interval) f
an approxim
(eCRF) will
specificatio
ve(s). eCRF
will be used
nagement)
System Org
w with the p
documents,
, laboratory
utomated in
treatment-ex
a HIV-1 RN
e LPV/r plu
d that a sim
ma HIV-1 R
is 196, a Si
using norma
from the ob
mate dropou
l be used. P
on will be d
F will be co
d to transm
and regulato
gan Classifi
patient and
data and re
data/inform
nstruments,
xperienced
NA level))
us 2 NRTi c
milar percent
RNA at week
imple Asym
al distributio
bserved prop
ut rate abou
Prior to set
eveloped by
ompleted fo
mit and colle
ory authorit
20
fication
source
ecords.
mation,
etc.
HIV-1
on the
control
tage of
k 48.
mptotic
on will
portion
t 10%,
t-up of
y CRO
or each
ect the
ties, as
Versi
appl
must
for
auto
infor
The
his/h
princ
subje
revie
9.14
The
Sinc
gene
with
mini
Qual
each
appr
Data
The
ion 01, dated 1
icable. Elec
t be entered
site staff
matically. D
rmation ente
investigato
her routine p
cipal investi
ect’s set of
ewed period
4
principal fe
ce this is an
eration of d
h number o
imum and
litative vari
h category.
ropriate.
a Analysis S
following a
Lopinavir/ritoP15-452 Prot
17 August 201
ctronic CRF
d by trained
during site
Data discrep
ered in the e
or will store
practice. Th
igator will r
f eCRFs b
dically for c
Data An
eatures of th
n open-label
descriptive s
f patients,
maximum
iables will b
Graphs m
Set
analysis pop
onavir and Lamtocol
15
Fs will be se
d and author
e initiation.
pancies dete
eCRFs must
e subject d
hese subject
review the e
y electronic
ompletenes
nalysis
he statistica
, non-rando
summary st
mean, stan
values, and
be summari
may be gene
pulations wil
mivudine
et by CRO d
rized person
. eCRF tra
ected by eCR
t also be ref
data in his/h
files will se
eCRFs for c
c signature
s, legibility
al analysis o
omized trial
tatistics. Qu
ndard deviat
d 95% CI
ized with th
erated for
ll be defined
designee as
n only. eCR
acks all ch
RF will be a
flected in th
her source
erve as sour
completenes
e where ind
and accepta
of the data
, the analys
uantitative v
tion, media
for mean
he number a
visual inter
d:
web based s
RF training w
hanges to
addressed to
e patient so
documents
rce data for
ss and accur
dicated. Th
ability by A
are describe
ses will prim
variables wi
an, 1st quar
or median
and proport
rpretation o
site. In eCR
will be perf
the entered
o investigat
urce docum
in accorda
the program
racy and sig
e eCRFs w
AbbVie/CRO
ed in this s
marily invol
ill be summ
rtile, 3rd qu
(as approp
tion of patie
of the resu
21
RF data
formed
d data
tor. All
ments.
ance to
m. The
gn each
will be
O.
ection.
lve the
marized
uartile,
priate).
ents in
ults, as
Versi
All
Use/
Enro
The
No i
Base
Base
statis
Ana
Num
HIV
asym
Ana
1. N
HIV
asym
2. A
chan
data)
gene
untra
ion 01, dated 1
Enrolled S
/Disclosure
olled Set be
primary and
imputations
eline Demo
eline demog
stics mentio
alysis of prim
mber and pro
V-1- RNA le
mptotic two-
alysis of seco
Number and
V-1- RNA le
mptotic two-
Absolute val
nge as comp
) will be s
erated for
ansformed d
Lopinavir/ritoP15-452 Prot
17 August 201
Set will inc
of Data for
used for all
d secondary
for missing
ographic an
graphic and
oned above.
mary endp
oportion of p
vel at week
-sided 95%
ondary end
proportion
evel at wee
-sided 95%
lues of HIV
pared to the
summarized
transforme
data.
onavir and Lamtocol
15
clude all p
rm to partic
l study analy
y effectivene
g data will b
nd Clinical C
d clinical ch
point
patients on
k 48 of the o
confidence
dpoints
of patients
ek 24 of the
confidence
V-1- RNA v
e baseline (
d with desc
d data an
mivudine
patients wh
cipate in the
yses.
ess analyses
be performed
Characteri
haracteristic
dual therapy
bservationa
interval for
on dual th
e observatio
interval for
viral load a
(untransform
cribed abov
nd 95% CI
ho signed A
e study and
s will be per
d.
istics
cs will be s
y (LPV/r +
al period wil
r a single pro
herapy (LPV
onal period
r a single pro
at baseline,
med and ba
ve statistics.
I for med
Authorizatio
have any c
rformed on t
summarized
3TC) with u
ll be present
oportion wi
V/r + 3TC)
will be pre
oportion wi
at weeks 2
ase-10 logar
. 95% CI f
dian will b
on (Consen
collected da
the observe
d with desc
undetectable
ted. A simp
ill be genera
with undete
esented. A
ill be genera
4 and 48 a
rithm transf
for mean w
be generate
22
nt) for
ata. All
d data.
criptive
e
le
ated.
ectable
simple
ated.
and the
formed
will be
ed for
Versi
3. A
chan
abov
4. N
prese
deve
num
enro
will
5. A
(arm
with
6. A
(mm
(mm
co
statis
7. N
repo
caus
prop
with
treat
code
ion 01, dated 1
Absolute val
nge as com
vementioned
Number and
ented separ
elops the re
mber of patie
olled in the s
be generate
Absolute val
m, hip and w
h described w
Absolute val
mol/L), insu
mol/L), trig
mpared to th
stics. 95% C
Number and
orted) [inclu
se deaths]wi
portion will
h non-seriou
tment disco
ed by Prefer
Lopinavir/ritoP15-452 Prot
17 August 201
lues of CD4
mpared to
d statistics.
d proportion
rately. The t
esistance div
ent who dev
study. An e
ed.
lues at wee
waist circum
with abovem
lues at wee
ulin (μEq/m
clycerides
he baseline
CIs for mean
d proportion
uding AE ca
ill be presen
be generate
us AEs, SA
ntinuations
rred Terms
onavir and Lamtocol
15
4+ T-cell c
the basel
95% CIs for
n of patien
two proport
vided on nu
velops the r
exact two-si
eks 24 and
mference in c
mentioned s
eks 24 and
ml), total ch
(mmol/L),
e will be s
ns will be g
n of patien
ausing treatm
nted. An ex
ed. The com
AEs, SAE in
will be pre
(PTs) cons
mivudine
ounts at the
line will b
r means wil
nts who de
tions will b
umber of p
resistance d
ided 95% co
48 and ch
cm) as comp
tatistics. 95
48 and cha
holesterol (
creatinine
summarized
generated.
nts with all
ment discon
xact two-sid
mmon table
ncluding SA
esented. Th
istent with
e baseline,
be summa
ll be generat
evelop resis
be presented
patients who
divided on n
onfidence in
hanges of an
pared to the
% CIs for m
anges of m
(mmol/L),
(μmol/L),
d with desc
l AEs (non
ntinuations]
ded 95% con
with all AE
AEs that cau
he tables of
the latest ve
at weeks 2
arized with
ted.
stance to ea
d: (1) numb
o had the re
number of p
nterval for a
nthropomet
baseline w
means will b
etabolic par
LDL- and
ALT (u/l)
cribed with
n-serious A
, SAEs, [inc
nfidence int
Es as well a
use deaths,
f AEs will b
ersion of M
24 and 48 a
h described
ach drug w
ber of patien
esistance te
patients who
a single prop
ric measure
will be summ
be generated
rameters (g
HDL-chol
, AST (u/
h abovemen
Es spontan
cluding SAE
terval for a
as separated
and AEs c
be generate
MedDRA (M
23
and the
d with
will be
nt who
est; (2)
o were
portion
ements
marized
d.
glucose
esterol
/l)) as
ntioned
neously
Es that
single
d tables
causing
d with
Medical
Versi
Dict
(incl
acco
com
inclu
frequ
9.15
The
assu
docu
appl
Stud
and
The
discr
will
Data
appr
data
Stud
in ac
ion 01, dated 1
tionary for
luding death
ording to PT
mmon AEs,
uded in the
uencies may
5
AbbVie rep
urance system
umented, an
icable local
dy protocol i
guidelines.
AbbVie re
repancies w
be made to
a Manageme
roved by Ab
process wit
dy report wi
ccordance w
Lopinavir/ritoP15-452 Prot
17 August 201
Regulatory
hs), non-seri
T frequencie
SAEs, and
e body of t
y be append
Quality
presentative
m is in plac
nd reported
l laws and re
is developed
epresentative
will be comm
the databas
ent Plan and
bbVie repre
thin the stud
ill be develo
with internal
onavir and Lamtocol
15
y Activities
ious AEs, an
es and by S
AEs causin
the report.
ded to the re
y Control
es are respon
ce to ensure
in complia
egulations.
d by AbbVi
e can moni
municated
se per applic
d Data Vali
esentative b
dy and respo
oped by CR
l templates a
mivudine
s) . Tables
nd AEs cau
OC, Severit
ng treatmen
A complete
port.
nsible for en
e that the pr
ance with th
ie Study Tea
itor the elec
to site for
cable EDC p
dation Spec
efore eCRF
onsible pers
RO and revi
and guidelin
will prese
using treatme
ty and Caus
nt discontinu
e tabulated
nsuring that
rogram is co
he protocol,
am in accor
ctronic case
clarification
procedures.
cification wi
F launch. Th
sonal.
iewed/appro
nes.
ent informa
ent disconti
sality. Summ
uation will
list of the
t a quality c
onducted an
, accepted s
rdance with
e report for
n. Any nece
ill be develo
hese docum
oved by Abb
ation about
inuation org
mary tables
be generate
se AEs and
control and q
nd data gen
standards an
internal tem
rms in EDC
essary corre
oped by CR
ments will de
bVie Study
24
SAEs
ganized
of the
ed and
d their
quality
erated,
nd any
mplates
C. Any
ections
RO and
escribe
y Team
Versi
9.16
The
cente
dual
patie
week
Ther
natu
thera
9.17
Not
10.0
This
(15)
Writ
prior
writt
will
All
indiv
The
of C
enro
ion 01, dated 1
6
study is pl
ers study w
therapy (L
ents with an
ks in the rou
refore, the l
ure and resul
apy (LPV/r
7
applicable.
0
s observation
and with Fe
tten authoriz
r to enrollin
ten authoriz
be made in
data will b
vidual patien
protocol an
Central and/o
ollment will
Lopinavir/ritoP15-452 Prot
17 August 201
Limitat
lanned as a
with no contr
LPV/r + 3T
n undetectab
utine clinica
limitations
lts of the stu
+ 3TC) in r
Other A
Protec
nal program
ederal Law
zation to us
ng each pat
zation will n
order to av
be captured
nts and hen
nd relevant p
or local (if a
start only a
onavir and Lamtocol
15
ions of the
a non-interv
rol group. T
TC) in pop
ble plasma
al settings o
of the stud
udy are valid
routine clini
Aspects
ction of H
m will be co
of 27 July 2
se and/or dis
tient in the
not be inclu
oid subject
and handl
ce patient c
program do
applicable)
after obtainin
mivudine
e Researc
ventional, p
The study is
pulation of
HIV-1 RN
f the Russia
dy based on
d only for u
ical settings
Human S
onducted in
2006 N 152-
sclose perso
program a
ded in the p
identifying
ed in such
onfidentiali
ocuments wi
Independen
ng written a
ch Methods
product-focu
aimed to a
f treatment-
NA level (fo
an Federatio
n its observ
understandin
in Russia.
Subjects
accordance
-FZ “On pe
onal and/or
and parents
program. Ho
information
a way so
ity will be m
ill be submi
nt Ethics Co
approval fro
s
used, longit
ccess the ef
-experienced
or at least 6
on.
vational and
ng of effecti
with Decla
rsonal data”
health data
not willing
owever, all
n (such as n
as to not r
maintained a
itted for rev
ommittee(s)
m the IEC.
udinal and
ffectiveness
d HIV-1 in
6 months) o
d non-compa
veness of th
aration of H
” (18).
must be ob
g to provid
reasonable
name, addres
reveal iden
at all times.
view and ap
(IEC) and p
25
multi-
of the
nfected
ver 48
arative
he dual
elsinki
btained
e such
efforts
ss, etc).
ntity of
pproval
patient
Versi
11.0
A Corelatreliadistr
ComrepoSect
11.1
11.1
An adoestherefindiwhet
Suchaccidpre-e
If aneven
De
Lif
ion 01, dated 1
0
omplaint is ted to the phability, safetribution.
mplaints assoorted to the Stions 11.1.1
1
1.1
adverse evens not necessaefore be anying), symptother or not t
h an event dental or intexisting con
n adverse evnt (SAE):
ath of Patie
fe-Threaten
Lopinavir/ritoP15-452 Prot
17 August 201
Manag
any writtenhysical charaty, effectiven
ociated withSponsor (Sethrough 11
Medica
AdversCatego
nt (AE) is darily have ay unfavorabom, or diseathe event is
can result frotentional ovndition or ill
vent meets a
ent:
ning:
onavir and Lamtocol
15
gement a
n, electronicacteristics, iness, or per
h any compoection 11.2.2.1.6. For pr
al Complai
se Event Dories
defined as ana causal relale and unintase temporaconsidered
om use of thverdose, drulness is cons
any of the fo
An e
An ewouinterincluoccu
mivudine
and Repo
, or oral comidentity, quaformance of
onent of this2). For adveroduct comp
nts
Definition a
ny untowardationship wittended sign
ally associatcausally rel
he drug as stg abuse, or sidered an a
ollowing crit
event that re
event that, iuld have resurvention hadude an evenurred in a m
orting of
mmunicationality, purityf a product/
s investigatierse events, plaints, plea
and Seriou
d medical octh their treat(including aed with the lated to the
tipulated in drug withdr
adverse even
teria, it is co
esults in the
in the opinioulted in immd not been tnt that would
more severe f
Complai
n that allegey, potency, d/device after
ional producplease refer
ase refer to S
us Advers
ccurrence intment. An aan abnormause of a meuse of the p
the labelingrawal. Anynt.
onsidered a
e death of a p
on of the invmediate fatataken. This d have beenform.
ints
es deficiencdurability, r it is release
ct must be r to Section 11.2
e Event
n a patient, wadverse eve
al laboratoryedicinal prodproduct.
g, as well as worsening
serious adv
patient.
vestigator, ality if medi
does not n fatal if it h
26
cies
ed for
2.
which ent can y duct,
s from of a
verse
cal
had
Versi
Ho
ProHo
Co
PerDis
ImReSurPre
11.1
The colle
ion 01, dated 1
ospitalizatio
olongation ospitalizatio
ongenital An
rsistent or sability/Inc
mportant Mequiring Mergical Interevent Serio
1.2
following dected as an e
Lopinavir/ritoP15-452 Prot
17 August 201
on:
ofon:
nomaly:
Significantcapacity:
edical Evenedical or rvention to ous Outcom
Severit
definitions wendpoint/da
onavir and Lamtocol
15
An efor aemefacil
An ehosp
An athat
t An einterpatieexpesuchinfluankl
nt
me:
An iimmhospjeopsurglistehospcongdisasponimpinclutreatdyscinpadepe
ty
will be used ata point in t
mivudine
event that reany length oergency roomlity.
event that opitalized and
anomaly detresults in fe
event that rerferes with tent. Disabileriences of rh as headachuenza, and ale).
important mmediately lifpitalization,pardize the pgical interveed above (i.epitalization,genital anom
ability/incapntaneous abortant mediude allergictment in an crasias or coatient hospitendency or
to rate the sthe study an
esults in an of time. Thim visit or ad
ccurs whiled prolongs t
tected at or etal loss.
esults in a cthe activitielity is not inrelatively mhe, nausea, vaccidental tr
medical evenfe-threatenin but based o
patient and mention to pree., death of p prolongatio
maly, or perpacity). Addortion or stical event. E
c bronchospaemergency
onvulsions ttalization, ordrug abuse.
severity for nd for all ser
admission tis does not idmission to
e the study pthe patient's
after birth,
ondition thaes of daily lintended to in
minor medicavomiting, drauma (e.g.,
nt that may nng or result on medical jmay requireevent any ofpatient, life on of hospitrsistent or siditionally, anillbirth is coExamples ofasm requirinroom or at
that do not rr the develo
any adverserious advers
to the hospitinclude an an outpatie
patient is s hospital sta
or any anom
at substantiaiving of a stunclude al significan
diarrhea, , sprained
not be in death or judgment me medical orf the outcomthreatening
talization, ignificant ny elective
onsidered anf such eventng intensivehome, bloo
result in opment of dr
e event beinse events.
27
tal
ent
ay.
maly
ally udy
nce
may r
mes g,
or n ts e d
rug
ng
Versi
Mi
Mo
Sev
11.1
The the u
Re
No
If nobe pr
11.1
Seriopatieuntil
11.1
In th
ion 01, dated 1
ild:
oderate:
vere:
1.3
following duse of produ
asonable P
o Reasonabl
o reasonablerovided for
1.4
ous adverseent's authoril 30 days fo
1.5
he event of a
For econtaawar
Lopinavir/ritoP15-452 Prot
17 August 201
The a
The apatie
The apatiethrea
Relatio
definitions wuct:
Possibility
le Possibilit
e possibilitythe adverse
Serious
e events willization to usllowing the
Serious
a serious adv
events fromact person ire of the eve
onavir and Lamtocol
15
adverse eve
adverse event's usual ac
adverse event's usual ac
atening.
nship to P
will be used
An advcausal event.
ty An advcausal event.
y of being ree event.
s Adverse
l be reportedse and disclointake of th
s Adverse
verse event,
m patients usdentified beent.
mivudine
nt is transie
nt causes thctivities.
nt causes coctivities and
Pharmaceu
to assess th
verse event relationship
verse event relationship
elated to pro
Event Co
d to AbbVieose informahe last dose
Event Re
, the physici
ing and Abbelow within
ent and easil
he patient di
onsiderable d may be inc
utical Prod
he relationsh
where therep between th
where therep between th
oduct is give
ollection P
e from the tiation (or the of physician
porting
ian will:
bVie produc24 hours of
ly tolerated
scomfort an
interferencecapacitating
duct
hip of the ad
e is evidencehe product a
e is no evidehe product a
en, an altern
eriod
ime the phypatient's in
n-prescribed
ct - notify thf the physic
by the patie
nd interrupts
e with the g or life
dverse event
e to suggestand the adve
ence to suggand the adve
nate etiology
ysician obtaiformed cond treatment.
he AbbVie ian becomin
28
ent.
s the
t to
t a erse
gest a erse
y must
ins the nsent) .
ng
Versi
Con
Back
11.1
In thcontawar
11.2
11.2
A Prdrug
For packdiscrmiss
ion 01, dated 1
ntact for SA
k-up contact
1.6
he event of tact person re of the pre
2
2.1
roduct Comg component
a product kaging, prodrepancies/insing compon
Lopinavir/ritoP15-452 Prot
17 August 201
AEs reportin
t for SAEs r
Pregna
a pregnancidentified i
egnancy.
Produc
Definiti
mplaint is ant of the prod
this may duct appearanadequaciesnents/produ
onavir and Lamtocol
15
ng:
reporting:
ancy Repo
cy occurrencin Section 1
ct Complai
ion
ny Complainduct.
include, buance whose in the labct, or packa
mivudine
rting
ce in the pa11.1.5 with
int
nt (see Secti
ut is not li color/markbeling/instru
aging issues
atient, the pin 24 hours
ion 11.0 for
imited to, kings do notructions (ex.
physician ws of the ph
r the definit
damaged/brt match the xample: p
will notify Ahysician bec
ion) related
roken prodlabeling, la
printing ille
29
AbbVie coming
d to the
duct or abeling egible),
Versi
11.2
ProdSponComfollothe SSponsumm
Prodthe i
Prodcondinvewith
The inve
Prim
ion 01, dated 1
2.2
duct Complnsor within
mplaint repoowed-up to Sponsor (or nsor. Produmary. All o
duct complaidentified co
duct Compldition. In instigator to
hin 30 days,
descriptionstigate and
mary contac
Lopinavir/ritoP15-452 Prot
17 August 201
Reporti
laints concen 24 hours orting practia satisfactoan authoriz
uct Complaiother compl
aints involviontact or ma
laints may nstances whreturn the pthe site will
n of the comdetermine i
ct for Prod
onavir and Lamtocol
15
ing
erning the of the studices. Produ
ory conclusized represenints associataints will be
ing a non-Spanufacturer,
require rehere a returnproduct witl need to pro
mplaint is imf any correc
duct Compl
mivudine
investigatiody site's knouct Complaion. All folntative) and ted with adve monitored
ponsor inveas necessar
eturn of then is requestthin 30 dayovide justifi
mportant foctive actions
aint report
onal produowledge of aints occurrillow-up infodocumented
verse eventsd on an ongo
estigational pry per local
e product ted, every eys. If returnfication and
or AbbVie is are require
ting:
ct must bef the event ing during
formation isd in source s will be repoing basis.
product shoregulations
with the aeffort shouldns cannot ban estimate
n order to eed.
e reported via local Pthe study w to be reporas required
ported in the
ould be repo.
alleged comd be made be accommd date of ret
enable Abb
30
to the Product will be rted to by the
e study
orted to
mplaint by the
modated turn.
bVie to
Versi
Back
12.0
At th
repo
meth
form
may
with
The
publ
PMO
after
scien
13.0
1.
2.
ion 01, dated 1
k-up contac
0
he end of th
ort author. T
hodology o
ms and the s
not be rele
hout express
study will
lished at th
OS will be p
r prior writ
ntific confer
0
Gatell JMLamivudMaintenaAIDS 20
M.J. RoloGARDEL
Lopinavir/ritoP15-452 Prot
17 August 201
ct for Prod
PlansResult
he study, a
This report
f the study
study repor
eased to un
s written app
be registere
his web-bas
published b
tten agreem
rences.
Refere
M et al. Nondine vs. Tripance of HIV14, Poster #
on et al. DuL study. AID
onavir and Lamtocol
15
duct Compl
for Dissets
study repo
will contain
y and its re
rt must be t
nauthorized
proval from
ed at www
sed resource
by AbbVie a
ment from A
ences
n-inferiority ple-Therapy V-1 Viral Su# LB PE17.
ual therapy inDS 2014, W
mivudine
aint report
eminatin
rt will be w
n a descript
esults and c
treated as th
people in a
AbbVie.
.ClinicalTri
e after inte
and/or by a
AbbVie in s
of Dual-Thwith LPV/r
uppression: 4
n key subgrWEPE080
ting:
ng and Co
written in co
tion of the
conclusions.
he confiden
any form (p
ials.gov and
ernal approv
ny one of t
scientific jo
herapy with Lr plus Two N48-Week Re
roups of trea
ommunic
ollaboration
objectives o
. The comp
ntial propert
publications
d results of
val. Also th
the participa
ournals and
Lopinavir/rNucleos(t)idesults of the
atment-naïv
cating St
n with CRO
of the PMO
pleted case
ty of AbbV
or presenta
the study w
he results o
ating investi
d presented
itonavir pludes for e OLÉ Study
ve patients in
31
tudy
O study
OS, the
report
Vie and
ations)
will be
of this
igators
at the
us
y.
n the
Versi
3.
4.
5.
6.
7.
8.
9.
10.
11.
ion 01, dated 1
Cahn et atherapy winhibitorsresults ofDis. 2014
ThompsoInternatio
Gallant Jassociatereverse-tr
D:A:D Sttranscriptenrolled i(9622): 1
Brinkmannucleosidpathogen354:1112
Arribas Jlopinaviranalysis.
Arribas Jor withouAIDS, 20
Paton et a2014 Abs
Pery CMpharmacoinfection
Lopinavir/ritoP15-452 Prot
17 August 201
al Dual therawith lopinavs in antiretrof the random4 Jul;14(7):5
on MA, Abeonal AIDS S
JE, Parish Med with tenoranscriptase
tudy Grouptase inhibitoin the D:A:D
1417-26
n K, Smeitinde-analoguenesis of antir2-1115.
JR, Delgador-ritonavir anJ Acquir Im
JR, Horban Aut nucleosid010; 24: 223
al RCT of Pstract 550LB
M and Fauldsokinetic pro". Drugs, 19
onavir and Lamtocol
15
apy with lopvir and ritonoviral-therap
mised, open 572-80
erg JA, CahnSociety_US
MA, Keruly Jfovir disopr
e inhibitor tr
, Sabin CA,ors and risk D study: a m
nk JA, Rome reverse-traretroviral-th
o R, Arranz And 2 nucleo
mmune Defi
A, Gerstoft de analogues3-30.
PI monotherB
s D. "Lamivoperties and 997, vol. 53
mivudine
pinavir and navir plus twpy-naive adlabel, non-i
n P, et al. ASA Panel. 20
JC, Moore Rroxil fumarareatment". C
, Worm SWof myocard
multi-cohort
mijn JA, Reianscriptase iherapy-relate
A et al. Loposides for maic Syndr, 20
J, et al."Thes, for patien
rapy switch
vudine: A retherapeutic, no4, pp. 6
ritonavir plwo nucleosiddults with Hinferiority G
Antiretrovira010;304:321
RD. "Changate treatmenClin Infect D
W, et al. "Usedial infarctiot collaborati
ss P. Mitochinhibitors is ed lipodystr
pinavir-ritonaintenance t
009; 51: 147
e MONET tnts with HIV
for long ter
view of its ac efficacy in57-80
lus lamivudide reverse tr
HIV-1 infectiGARDEL tri
al Recomme1-333 JAMA
ges in renal nt, comparedDis, 2005; 4
e of nucleoson in HIV-inion". Lancet
hondrial toxa key facto
rophy. Lanc
navir monottherapy of H
7-52.
trial: darunaV RNA belo
rm HIV man
antiviral actn the manage
ine versus trranscriptaseion: 48 weeial. Lancet I
endations ofA.
function d with nucle
40(8): 1194-
side reverse nfected patit, 2008. 371
xicity induceor in the cet. 1999;
therapy versHIV: 96-we
avir/ritonaviw 50 copies
nagement. C
tivity, ement of HI
32
riple e k Infect
f the
eoside 8
ients 1
ed by
sus ek
ir with s/mL"
CROI
IV
Versi
12.
13.
14.
15.
16.
ion 01, dated 1
Cleary S,priority s
Benson Clopinavirin humanpatients.
Murphy RlopinavirHIV Clin
WMA DeHuman S
17. Feder
Lopinavir/ritoP15-452 Prot
17 August 201
, McIntyre Dsetting". Hea
CA, Deeks Sr/ritonavir pln immunodeJ Infect Dis
RL, da Silvar/ritonavir-bn Trials 200
eclaration oSubjects, 20
ral Law of 2
onavir and Lamtocol
15
DE. "Affordalth Econ, 2
SG, Brun SClus nevirapieficiency virs 2002;185:5
a BA, Hicksbased regime8;9:1-10
of Helsinki -13.
27 July 2006
mivudine
dability: The2009;18:373
C, et al. Safeine and 2 nurus type 1-in599-607
s CB, et al. en in antiret
- Ethical Pri
6 N 152-FZ
e forgotten c3-75
fety and antiucleoside revnfected prot
Seven-year troviral-naiv
inciples for
Z “ON PERS
criterion in
iviral activitverse-transctease inhibit
efficacy of ve HIV-1-in
Medical Re
SONAL DA
health-care
ty at 48 weecriptase inhitor-experien
f a nfected patie
esearch Invo
ATA”.
33
eks of ibitors nced
ents.
olving